Search For "biocon ltd"
Pharma firm Biocon's Q4 net profits up 31 pc; announces dividend for inves
Updated : 2 years, 10 months ago IST
Global biopharmaceuticals company Biocon has announced its consolidated financial results for the fourth quarter and the fiscal year that ended on March 31, 2023.
Read More
Biocon Biologics completes acquisition of Viatris' Global Biosimilars Busi
Updated : 3 years, 3 months ago IST
Bengaluru (Karnataka) [India], November 30 (ANI/PRNewswire): Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), announced today that it has successfully completed its multi-billion-dollar (USD) acquisition of the global biosimilars business of its partner Vi
Read More
Biocon Q2FY23 Revenue at Rs 2,384 Cr., Up 23 percent; Core EBITDA at Rs 81
Updated : 3 years, 4 months ago IST
Bengaluru (Karnataka) [India], November 15 (ANI/NewsVoir): Biocon Ltd, an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the second quarter ended September 30, 2022.
Read More
Biocon Biologics to acquire Viatris' Biosimilars Assets for up to USD 3.33
Updated : 4 years ago IST
Bengaluru (Karnataka) [India], March 1 (ANI/PR Newswire): Biocon Biologics Ltd, a subsidiary of Biocon Ltd (BSE code: 532523) (NSE: BIOCON), has entered into a definitive agreement with its partner Viatris Inc. (NASDAQ: VTRS). Accordingly, Biocon Biologics Ltd (BBL) will acquire Viatris'
Read More
Biocon Biologics to offer 15 pc stake to Serum Institute Life Sciences at
Updated : 4 years, 6 months ago IST
Bengaluru (Karnataka) [India], September 17 (ANI): Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS) announced a strategic alliance on Thursday and BBL said it will offer around 15 per cent stake to SILS at a post-money valua
Read More
Biocon posts Rs 257 crore profit for Q4 on strong biosimilar business
Updated : 4 years, 11 months ago IST
Bengaluru (Karnataka) [India], April 29 (ANI): Biopharmaceuticals major Biocon Ltd on Thursday reported net profit of Rs 257 crore in the fourth quarter of FY21, up 95 per cent from Rs 132 crore in Q4 FY20.
Read More
Biocon Biologics partners with IDF to promote diabetes care
Updated : 5 years, 1 month ago IST
Bengaluru (Karnataka) [India], February 16 (ANI): Biocon Biologics has partnered with the International Diabetes Federation (IDF) as the first biosimilar insulin company to promote and support IDF's core mission initiative and activities.
Read More
Biocon reports 17 pc dip in Q3 net profit at Rs 169 cr
Updated : 5 years, 2 months ago IST
Bengaluru (Karnataka) [India], January 22 (ANI): Biopharmaceuticals major Biocon Ltd has reported 17 per cent decline in its net profit to Rs 169 crore during the quarter ended December while the company's topline grew by 7 per cent to Rs 1,879 crore.
Read More
Biocon appoints Anupam Jindal as new CFO
Updated : 5 years, 6 months ago IST
Bengaluru (Karnataka) [India], September 23 (ANI): Biocon Ltd has appointed Anupam Jindal as the new Chief Financial Officer (CFO) and be part of the executive leadership team.
Read More
Biocon stock falls 2 pc after 28 pc fall in Q1 net profit
Updated : 5 years, 8 months ago IST
Mumbai (Maharashtra) [India], July 24 (ANI): Shares of Biocon Ltd fell by nearly 2 per cent on Friday morning after the biopharmaceutical major posted 28 per cent fall in its June quarter (Q1 FY21) net profit at Rs 149 crore.
Read More
Biocon Biologics and Voluntis join hands for global collaboration on dig
Updated : 5 years, 8 months ago IST
Bengaluru (Karnataka) [India], July 21 (ANI): Biocon Biologics India Limited, a fully integrated 'pure-play' biosimilars company, a subsidiary of Biocon Ltd. on Tuesday announced a global collaboration agreement between Biocon Biologics' subsidiary Biocon Sdn. Bhd., Malaysia and Voluntis to
Read More
Biocon's drug Itolizumab gets DCGI nod for use in moderate to severe Covid
Updated : 5 years, 8 months ago IST
Bengaluru (Karnataka) [India], July 11 (ANI): Biopharmaceutical major Biocon Ltd said on Saturday it has received approval from the Drugs Controller General of India (DCGI) to market Itolizumab injection 25mg/5ml solution for emergency use in India for the treatment of cytokine release syndr
Read More